Jaguar Health Stock Price, News & Analysis (NASDAQ:JAGX) $0.32 -0.07 (-17.77%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$0.31▼$0.3850-Day Range$0.23▼$0.4652-Week Range$0.21▼$9.53Volume7.83 million shsAverage Volume2.72 million shsMarket Capitalization$16.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Jaguar Health MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.83) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.38 out of 5 starsMedical Sector896th out of 948 stocksPharmaceutical Preparations Industry406th out of 423 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Jaguar Health. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.27% of the float of Jaguar Health has been sold short.Short Interest Ratio / Days to CoverJaguar Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jaguar Health has recently decreased by 26.08%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJaguar Health does not currently pay a dividend.Dividend GrowthJaguar Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JAGX. Previous Next 2.0 News and Social Media Coverage News SentimentJaguar Health has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Jaguar Health this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for JAGX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Jaguar Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jaguar Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.16% of the stock of Jaguar Health is held by insiders.Percentage Held by InstitutionsOnly 12.24% of the stock of Jaguar Health is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jaguar Health are expected to grow in the coming year, from ($5.83) to ($0.40) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Jaguar Health Stock (NASDAQ:JAGX)Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Read More JAGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAGX Stock News HeadlinesDecember 4, 2023 | msn.comFDA renews conditional approval for Jaguar canine chemo drugDecember 4, 2023 | finance.yahoo.comFDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in DogsDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 1, 2023 | americanbankingnews.comJaguar Health (NASDAQ:JAGX) Coverage Initiated by Analysts at StockNews.comNovember 30, 2023 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health to Present December 5 at the MedInvest Oncology Investor ConferenceNovember 30, 2023 | finance.yahoo.comJaguar Health to Present December 5 at the MedInvest Oncology Investor ConferenceNovember 22, 2023 | msn.comJaguar Health falls after update on Phase 3 trial for plant-based drugNovember 21, 2023 | msn.comJaguar Health’s stock drops after results supporting ‘paramount’ trial have not been received yetDecember 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 21, 2023 | finance.yahoo.comTop Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy ForthcomingNovember 15, 2023 | finance.yahoo.comJaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Call TranscriptNovember 15, 2023 | finance.yahoo.comFILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTSNovember 14, 2023 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comJaguar Health Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | benzinga.comEarnings Preview For Jaguar HealthNovember 9, 2023 | finance.yahoo.comBreast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer SymposiumNovember 7, 2023 | finance.yahoo.comREMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM ESTNovember 2, 2023 | finance.yahoo.comJaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East MarketsNovember 1, 2023 | finanznachrichten.deJaguar Health, Inc.: Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel SyndromeNovember 1, 2023 | finance.yahoo.comIssuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)October 30, 2023 | finance.yahoo.comMagdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small PlanetOctober 26, 2023 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health to Present November 1st at Emerging Growth ConferenceOctober 26, 2023 | finance.yahoo.comJaguar Health to Present November 1st at Emerging Growth ConferenceOctober 25, 2023 | finance.yahoo.comNapo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th at the San Antonio Breast Cancer SymposiumOctober 23, 2023 | finance.yahoo.comMagdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health IndicationsOctober 19, 2023 | finance.yahoo.comIndependent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood DiseaseOctober 18, 2023 | finance.yahoo.comNapo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription DrugSee More Headlines Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/17/2021Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JAGX CUSIPN/A CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,450,000.00 Net Margins-370.40% Pretax Margin-380.79% Return on Equity-1,191.67% Return on Assets-79.95% Debt Debt-to-Equity Ratio22.00 Current Ratio1.77 Quick Ratio1.10 Sales & Book Value Annual Sales$11.96 million Price / Sales1.43 Cash FlowN/A Price / Cash FlowN/A Book Value($0.32) per share Price / Book-1.05Miscellaneous Outstanding Shares50,760,000Free Float50,675,000Market Cap$17.11 million OptionableNot Optionable Beta1.68 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Lisa A. Conte (Age 64)Founder, CEO, President & Director Comp: $771.4kDr. Pravin R. Chaturvedi Ph.D. (Age 60)Chief Scientific Officer & Chair of Scientific Advisory Board Comp: $539.04kMr. Jonathan S. Wolin CPA (Age 60)J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel Comp: $520.29kMr. Ian H. Wendt M.B.A. (Age 55)Chief Commercial Officer Comp: $441.31kDr. Steven R. King Ph.D. (Age 65)Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary Comp: $477.66kMs. Carol R. Lizak M.B.A. (Age 59)Chief Financial Officer Mr. Peter HodgeSenior Director of Investor Relations, Business Development & Special EventsDr. Karen J. Brunke Ph.D. (Age 71)Executive VP of Corporate & Business Development Mr. David SesinChief Manufacturing OfficerMore ExecutivesKey CompetitorsLixte BiotechnologyNASDAQ:LIXTLipella PharmaceuticalsNASDAQ:LIPOCadrenal TherapeuticsNASDAQ:CVKDFlora GrowthNASDAQ:FLGCGraybug VisionNASDAQ:GRAYView All Competitors JAGX Stock Analysis - Frequently Asked Questions How have JAGX shares performed in 2023? Jaguar Health's stock was trading at $0.0869 on January 1st, 2023. Since then, JAGX shares have increased by 272.8% and is now trading at $0.3240. View the best growth stocks for 2023 here. Are investors shorting Jaguar Health? Jaguar Health saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 827,900 shares, a decrease of 26.1% from the October 31st total of 1,120,000 shares. Based on an average daily trading volume, of 4,860,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.3% of the company's stock are short sold. View Jaguar Health's Short Interest. When is Jaguar Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our JAGX earnings forecast. How were Jaguar Health's earnings last quarter? Jaguar Health, Inc. (NASDAQ:JAGX) posted its quarterly earnings results on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The biotechnology company earned $0.63 million during the quarter. Jaguar Health had a negative net margin of 370.40% and a negative trailing twelve-month return on equity of 1,191.67%. During the same quarter in the previous year, the company posted ($0.63) earnings per share. When did Jaguar Health's stock split? Jaguar Health shares reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT). When did Jaguar Health IPO? (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. Who are Jaguar Health's major shareholders? Jaguar Health's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Jaguar Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:JAGX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaguar Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.